[1]陈心传,刘霆,贾永前,等.熊去氧胆酸治疗异基因造血干细胞移植术后早期胆汁淤滞性肝病观察[J].陆军军医大学学报(原第三军医大学学报),2009,31(03):251-253.
 CHEN Xin-chuan,LIU Ting,JIA Yong-qian,et al.Ursodeoxycholic acid in treatment of early cholestatic liver disease after allogeneic stem cell transplantation: report of 26 cases[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(03):251-253.
点击复制

熊去氧胆酸治疗异基因造血干细胞移植术后早期胆汁淤滞性肝病观察(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
31卷
期数:
2009年第03期
页码:
251-253
栏目:
论著
出版日期:
2009-02-15

文章信息/Info

Title:
Ursodeoxycholic acid in treatment of early cholestatic liver disease after allogeneic stem cell transplantation: report of 26 cases
作者:
陈心传刘霆贾永前何川李建军黄杰
四川大学华西医院血液内科
Author(s):
CHEN Xin-chuan LIU Ting JIA Yong-qian HE Chuan LI Jian-jun HUANG Jie
Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
关键词:
异基因造血干细胞移植术胆汁淤滞性肝病熊去氧胆酸S-腺苷蛋氨酸
Keywords:
allogeneic hematopoietic stem cell transplantation cholestatic liver diseases ursodeoxycholic acid s-adenosyl methionine
分类号:
R285.5; R457.7; R575.22
文献标志码:
A
摘要:
目的    探讨熊去氧胆酸(ursodeoxycholic acid ,UDCA)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation, allo-HSCT)术后早期胆汁淤滞性肝病的价值。    方法    选取2003-2007年本院行allo-HSCT术后诊断早期胆汁淤滞性肝病患者26例,序贯入组,分为观察组(12 例)和对照组(14 例)。观察组应用UDCA口服14 mg·kg-1·d-1 ,治疗14 d;对照组S-腺苷蛋氨酸静脉点滴,1 g/d, 治疗14 d。治疗前后分别检测2组患者总胆红素(TB)、直接胆红素(DB)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(GGT)及血清碱性磷酸酶(ALP)的含量,并观察治疗效果。    结果    观察组显效7例,有效3例, 无效2例; 对照组显效3例,有效3例, 无效8例。    结论    UDCA治疗allo-HSCT术后早期胆汁淤滞性肝病安全有效,患者耐受良好。
Abstract:
Objective    To evaluate the effect of ursodeoxycholic acid (UDCA) in cholestatic liver disease at early stage in patients after allogeneic hematopoietic stem cell transplantation.     Methods    Twenty-six consecutive cases of cholestatic liver diseases after allogeneic hematopoietic stem cell transplantation were enrolled and randomly divided into 2 groups, the UDCA group (n=12) and the s-adenosyl methionine group (n=14). They received conventional pre-transplantation chemotherapy, and regular prevention and treatment for graft versus host disease. The patients of the UDCA group were taken UDCA tables at a dose of 14 mg·kg-1·d-1 for 14 d, and those out of the other group were intravenously infused with s-adenosyl methionine at a dose of 1 g/d for 14 d. Clinical evaluation and laboratory testing for alanine aminotransferases (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL) and direct bilirubin (DBIL) were assessed pre- and post- treatment. TBIL reduced by ≥75%, ≥50% or ≤50% were regarded as marked effective, effective or ineffective.     Results    At the end of the treatment, the 7/12 of patients treated with UDCA had gotten marked effective, the 3/12 gotten effective, whereas 3/12 ineffective. In the s-adenosyl methionine group, ratio of the 3 outcomes were 3/14, 3/14 and 8/14 respectively. Compared with pre-therapy, there was a significant decrease in the serum ALT, ALP and GGT levels after treatment in both group (P<0.05). All patients completed their assigned treatment with no major adverse event.     Conclusion    UDCA  therapy appears to be effective, safe and tolerable in individuals with cholestatic liver diseases in allogeneic hematopoietic stem cell transplantation.
更新日期/Last Update: 2009-02-11